Reimagining the Framework Supporting the Static Analysis of Transporter Drug Interaction Risk; Integrated Use of Biomarkers to Generate Pan‐Transporter Inhibition Signatures

Evaluation of the Effect of Abrocitinib on Drug Transporters by Integrated Use of Probe Drugs and Endogenous Biomarkers

(2022) Manoli Vourvahis et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Renal transporter‐mediated drug‐biomarker interactions of the endogenous substrates creatinine and N 1 ‐methylnicotinamide: a PBPK modeling approach

(2022) Denise Türk et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Effect of a Ketohexokinase Inhibitor (PF‐06835919) on In Vivo OATP1B Activity: Integrative Risk Assessment Using Endogenous Biomarker and a Probe Drug

(2022) David A. Tess et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Assessing the Effect of Organic Anion Transporter Inhibition on Circulating Pyridoxic Acid, an Endogenous Transporter Biomarker, using Physiologically‐based Pharmacokinetic Modeling

(2022) Aarzoo Thakur et al.   FASEB JOURNAL

Further Evaluation of Coproporphyrins as Clinical Endogenous Markers for OATP1B

(2021) Sheng Feng et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Exploring the Use of Serum‐Derived Small Extracellular Vesicles as Liquid Biopsy to Study the Induction of Hepatic Cytochromes P450 and Organic Anion Transporting Polypeptides

(2021) A. David Rodrigues et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Regulatory guidelines do not accurately predict tolvaptan and metabolite interactions at BCRP, OATP1B1, and OAT3 transporters

(2021) Susan E. Shoaf et al.   CTS-Clinical and Translational Science

Evaluation of Ipatasertib Interactions with Itraconazole and Coproporphyrin I and III in a Single Drug Interaction Study in Healthy Subjects

(2021) Rucha S. Sane et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Quantitative prediction of breast cancer resistant protein mediated drug‐drug interactions using physiologically‐based pharmacokinetic modeling

(2021) Chester Costales et al.   CPT-Pharmacometrics & Systems Pharmacology

Acute and Chronic Effects of Rifampin on Letermovir Suggest Transporter Inhibition and Induction Contribute to Letermovir Pharmacokinetics

(2021) Jonathan A. Robbins et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Biomarker‐Informed Model‐Based Risk Assessment of Organic Anion Transporting Polypeptide 1B Mediated Drug‐Drug Interactions

(2021) Emi Kimoto et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Alteration in the plasma concentrations of endogenous OATP1B-biomarkers in non-small cell lung cancer patients treated with paclitaxel

(2020) Daiki Mori et al.   DRUG METABOLISM AND DISPOSITION

Recent progress in in vivo phenotyping technologies for better prediction of transporter-mediated drug–drug interactions

(2020) Kazuya Maeda   Drug Metabolism and Pharmacokinetics

Nicotinic acid transport into human liver involves organic anion transporter 2 (SLC22A7)

(2020) Sumathy Mathialagan et al.   BIOCHEMICAL PHARMACOLOGY

Metabolic interactions between peroxisomes and mitochondria with a special focus on acylcarnitine metabolism

(2020) Sander M. Houten et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

A Multiplexed HILIC-MS/HRMS Assay for the Assessment of Transporter Inhibition Biomarkers in Phase I Clinical Trials: Isobutyryl-Carnitine as an Organic Cation Transporter (OCT1) Biomarker

(2020) Lina Luo et al.   ANALYTICAL CHEMISTRY

Validation of a Drug Transporter Probe Cocktail Using the Prototypical Inhibitors Rifampin, Probenecid, Verapamil, and Cimetidine

(2020) Sabrina T. Wiebe et al.   CLINICAL PHARMACOKINETICS

A Microdose Cocktail to Evaluate Drug Interactions in Patients with Renal Impairment

(2020) Daniel A. Tatosian et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Detection of Weak Organic Anion-Transporting Polypeptide (OATP) 1B Inhibition by Probenecid (PROB) with Plasma-Based Coproporphyrin in Humans

(2020) Yueping Zhang et al.   DRUG METABOLISM AND DISPOSITION

An updated review of pharmacokinetic drug interactions and pharmacogenetics of statins

(2020) Takeshi Hirota et al.   Expert Opinion on Drug Metabolism & Toxicology

OATP-mediated hepatic uptake of glucuronide metabolites of androgens

(2020) Cindy Yanfei Li et al.   MOLECULAR PHARMACOLOGY

Identification of Appropriate Endogenous Biomarker for Risk Assessment of Multidrug and Toxin Extrusion Protein‐Mediated Drug‐Drug Interactions in Healthy Volunteers

(2020) Takeshi Miyake et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Identification of Glycochenodeoxycholate 3‐O‐glucuronide and Glycodeoxycholate 3‐O‐glucuronide as Highly Sensitive and Specific OATP1B1 Biomarkers

(2020) Mikko Neuvonen et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Coproporphyrin I Can Serve as an Endogenous Biomarker for OATP1B1 Inhibition: Assessment Using a Glecaprevir/Pibrentasvir Clinical Study

(2020) Hari V. Kalluri et al.   CTS-Clinical and Translational Science

Calibrating the in vitro-in vivo correlation for OATP mediated drug-drug interactions with rosuvastatin using static and PBPK models

(2020) Rucha Sane et al.   DRUG METABOLISM AND DISPOSITION

Current progress in identifying endogenous biomarker candidates for drug transporter phenotyping and their potential application to drug development

(2020) Tatsuki Mochizuki et al.   Drug Metabolism and Pharmacokinetics

Drug Metabolites Potently Inhibit Renal Organic Anion Transporters, OAT1 and OAT3

(2020) Ling Zou et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Impact of direction of transport on the evaluation of inhibition potencies of multidrug and toxin extrusion protein 1 (MATE1) inhibitors

(2020) Asami Saito et al.   DRUG METABOLISM AND DISPOSITION

Physiologically Based Pharmacokinetic Models of Probenecid and Furosemide to Predict Transporter Mediated Drug-Drug Interactions

(2020) Hannah Britz et al.   PHARMACEUTICAL RESEARCH

Clinical Aspects of Transporter-Mediated Drug-Drug Interactions

(2019) Arne Gessner et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Estimation of changes in serum creatinine and creatinine clearance caused by renal transporter inhibition in healthy subjects

(2019) Tomohisa Nakada et al.   Drug Metabolism and Pharmacokinetics

Clinical Studies on Drug‐Drug Interactions Involving Metabolism and Transport: Methodology, Pitfalls and Interpretation

(2019) Aleksi Tornio et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Phenotyping of Human CYP450 Enzymes by Endobiotics: Current Knowledge and Methodological Approaches

(2019) Gaëlle Magliocco et al.   CLINICAL PHARMACOKINETICS

Organic Anion Transporter Polypeptide 1B1 Polymorphism Modulates the Extent of Drug–Drug Interaction and Associated Biomarker Levels in Healthy Volunteers

(2019) Sook Wah Yee et al.   CTS-Clinical and Translational Science

A systematic in vitro investigation of the inhibitor preincubation effect on multiple classes of clinically relevant transporters

(2019) Peter Tatrai et al.   DRUG METABOLISM AND DISPOSITION

No Inhibition of MATE1/2K-Mediated Renal Creatinine Secretion Predicted With Ritonavir or Cobicistat

(2019) Ryota Kikuchi et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

GDC-0810 pharmacokinetics and transporter-mediated drug interaction evaluation with an endogenous biomarker in the first-in-human, dose escalation study

(2019) Kit Wun Kathy Cheung et al.   DRUG METABOLISM AND DISPOSITION

Renal Excretion of Dabigatran: The Potential Role of Multidrug and Toxin Extrusion (MATE) Proteins

(2019) Hong Shen et al.   MOLECULAR PHARMACEUTICS

Complex DDI by Fenebrutinib and the Use of Transporter Endogenous Biomarkers to Elucidate the Mechanism of DDI

(2019) Nicholas S. Jones et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Variability in In Vitro OATP 1B1/1B3 Inhibition Data: Impact of Incubation Conditions on Variability and Subsequent Drug Interaction Predictions

(2019) Savannah J. McFeely et al.   CTS-Clinical and Translational Science

Elucidation of N1-methyladenosine as a potential surrogate biomarker for drug interaction studies involving renal organic cation transporters

(2019) Takeshi Miyake et al.   DRUG METABOLISM AND DISPOSITION

Dose‐Dependent Inhibition of OATP1B by Rifampicin in Healthy Volunteers: Comprehensive Evaluation of Candidate Biomarkers and OATP1B Probe Drugs

(2019) Daiki Mori et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Gaining Mechanistic Insight Into Coproporphyrin I as Endogenous Biomarker for OATP1B-Mediated Drug-Drug Interactions Using Population Pharmacokinetic Modeling and Simulation

(2018) Shelby Barnett et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Further Studies to Support the Use of Coproporphyrin I and III as Novel Clinical Biomarkers for Evaluating the Potential for Organic Anion Transporting Polypeptide 1B1 and OATP1B3 Inhibition

(2018) Hong Shen et al.   DRUG METABOLISM AND DISPOSITION

Effect of OATP1B1/1B3 Inhibitor GDC-0810 on the Pharmacokinetics of Pravastatin and Coproporphyrin I/III in Healthy Female Subjects

(2018) Lichuan Liu et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Comparative Study of the Dose-Dependence of OATP1B Inhibition by Rifampicin Using Probe Drugs and Endogenous Substrates in Healthy Volunteers

(2018) Issey Takehara et al.   PHARMACEUTICAL RESEARCH

Biomarkers for In Vivo Assessment of Transporter Function

(2018) Fabian Müller et al.   PHARMACOLOGICAL REVIEWS

LC–MS/MS assay for N1-methylnicotinamide in humans, an endogenous probe for renal transporters

(2018) Lina Luo et al.   Bioanalysis

A multiplex HRMS assay for quantifying selected human plasma bile acids as candidate OATP biomarkers

(2018) Brian Rago et al.   Bioanalysis

Effect of tyrosine kinase inhibitors on renal handling of creatinine by MATE1

(2018) Saki Omote et al.   Scientific Reports

Transporters in Drug Development: 2018 ITC Recommendations for Transporters of Emerging Clinical Importance

(2018) Maciej J. Zamek-Gliszczynski et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Effect of OATP1B1 genotypes on plasma concentrations of endogenous OATP1B1 substrates and drugs, and their association in healthy volunteers

(2018) Daiki Mori et al.   Drug Metabolism and Pharmacokinetics

Clinical Probes and Endogenous Biomarkers as Substrates for Transporter Drug-Drug Interaction Evaluation: Perspectives From the International Transporter Consortium

(2018) Xiaoyan Chu et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

From Endogenous Compounds as Biomarkers to Plasma‐Derived Nanovesicles as Liquid Biopsy; Has the Golden Age of Translational PK ‐ ADME ‐ DDI Science Finally Arrived?

(2018) David Rodrigues et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Comprehensive Evaluation of the Utility of 20 Endogenous Molecules as Biomarkers of OATP1B Inhibition Compared with Rosuvastatin and Coproporphyrin I

(2018) Shelby Barnett et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Evidence for the Validity of Pyridoxic Acid (PDA) as a Plasma-Based Endogenous Probe for OAT1 and OAT3 Function in Healthy Subjects

(2018) Hong Shen et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Organic anion transporting polypeptide 2B1 – More than a glass-full of drug interactions

(2018) Savannah J. McFeely et al.   PHARMACOLOGY & THERAPEUTICS

Investigation of Glycochenodeoxycholate Sulfate and Chenodeoxycholate Glucuronide as Surrogate Endogenous Probes for Drug Interaction Studies of OATP1B1 and OATP1B3 in Healthy Japanese Volunteers

(2017) Issey Takehara et al.   PHARMACEUTICAL RESEARCH

Organic Anion Transporter 2: An Enigmatic Human Solute Carrier

(2016) Hong Shen et al.   DRUG METABOLISM AND DISPOSITION

Metformin and cimetidine: Physiologically based pharmacokinetic modelling to investigate transporter mediated drug–drug interactions

(2016) H.J. Burt et al.   EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

Comparing Various In Vitro Prediction Criteria to Assess the Potential of a New Molecular Entity to Inhibit Organic Anion Transporting Polypeptide 1B1

(2016) Jayabharathi Vaidyanathan et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Validation of a total IC50 method which enables in vitro assessment of transporter inhibition under semi-physiological conditions

(2016) Ryota Kikuchi et al.   XENOBIOTICA

Population pharmacokinetics of rifampicin and 25-deacetyl-rifampicin in healthy Asian adults

(2015) Kok-Yong Seng et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Prediction of Pharmacokinetics and Drug–Drug Interactions When Hepatic Transporters are Involved

(2014) Rui Li et al.   CLINICAL PHARMACOKINETICS

N1-methylnicotinamide as an endogenous probe for drug interactions by renal cation transporters: studies on the metformin–trimethoprim interaction

(2014) Fabian Müller et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Inhibitory effects of p-aminohippurate and probenecid on the renal clearance of adefovir and benzylpenicillin as probe drugs for organic anion transporter (OAT) 1 and OAT3 in humans

(2014) Kazuya Maeda et al.   EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

Mechanistic interpretation of conventional Michaelis–Menten parameters in a transporter system

(2014) Diana Vivian et al.   EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

Reduced Renal Clearance of Cefotaxime in Asians with a Low-Frequency Polymorphism of OAT3 (SLC22A8)

(2013) Sook Wah Yee et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Investigation of Endogenous Compounds for Assessing the Drug Interactions in the Urinary Excretion Involving Multidrug and Toxin Extrusion Proteins

(2013) Koji Kato et al.   PHARMACEUTICAL RESEARCH

Transporter-Mediated Drug–Drug Interactions Involving OATP Substrates: Predictions Based on In Vitro Inhibition Studies

(2012) K Yoshida et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

N-Methylnicotinamide Is an Endogenous Probe for Evaluation of Drug–Drug Interactions Involving Multidrug and Toxin Extrusions (MATE1 and MATE2-K)

(2012) S Ito et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Impact ofSLCO1B1(OATP1B1) andABCG2(BCRP) genetic polymorphisms and inhibition on LDL-C lowering and myopathy of statins

(2011) Grant T. Generaux et al.   XENOBIOTICA

Identification of inhibitor concentrations to efficiently screen and measure inhibition Ki values against solute carrier transporters

(2010) Xiaowan Zheng et al.   EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

ABCG2 Polymorphism Markedly Affects the Pharmacokinetics of Atorvastatin and Rosuvastatin

(2009) J E Keskitalo et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Bile Acid Sulfation: A Pathway of Bile Acid Elimination and Detoxification

(2009) Yazen Alnouti   TOXICOLOGICAL SCIENCES

Population Pharmacokinetics of Rifampin in Pulmonary Tuberculosis Patients, Including a Semimechanistic Model To Describe Variable Absorption

(2008) J. J. Wilkins et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Aldehyde Oxidase-Catalyzed Metabolism of N1-Methylnicotinamide in Vivo and in Vitro in Chimeric Mice with Humanized Liver

(2008) S. Kitamura et al.   DRUG METABOLISM AND DISPOSITION